Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients

Review of Diabetic Studies

Volumn 10, Issue 2-3, 2013, Pages 88-100

  Chen, Szu Chi ^a   Tseng, Chin Hsiao ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Cardiovascular disease; Chronic kidney disease; Dyslipidemia; Type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; ATENOLOL; ATORVASTATIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRBESARTAN; LAROPIPRANT; LIVER TRIACYLGLYCEROL LIPASE; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALBUMINURIA; ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOCHOLESTEROLEMIA; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MACROALBUMINURIA; META ANALYSIS (TOPIC); MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; KIDNEY DISEASES; RISK FACTORS;

EID: 84891757791     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2013.10.88     Document Type: Review

References (121)

1. International Diabetes Federation Diabetes Atlas Update 2012. http://www.idf.org/diabetesatlas/5e/Update2012.
2. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979. 241(19):2035-2038.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes care 1993. 16(2):434-444.
4. Tseng CH. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care 2004. 27(7):1605-1609.
5. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998. 339(4):229-234.
6. Hadaegh F, Fahimfar N, Khalili D, Sheikholeslami F, Azizi F. New and known type 2 diabetes as coronary heart disease equivalent: results from 7.6 year follow up in a Middle East population. Cardiovasc Diabetol 2010. 9: 84.
7. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke F, Buch P, Madsen M, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008. 117(15):1945-1954.
8. Chuang SY, Hsu PF, Sung SH, Chou P, Chen CH. Diabetes and 15-year cardiovascular mortality in a Chinese population: Differential impact of hypertension and metabolic syndrome. J Chin Med Assoc 2010. 73(5):234-240.
9. Deedwania PC. Diabetes is a vascular disease: the role of endothelial dysfunction in pathophysiology of cardiovascular disease in diabetes. Cardiol Clin 2004. 22(4):505-509.
10. Battisti WP, Palmisano J, Keane WE. Dyslipidemia in patients with type 2 diabetes. relationships between lipids, kidney disease and cardiovascular disease. Clin Chem Lab Med 2003. 41(9):1174-1181.
11. Tai TY, Tseng CH, Sung SM, Huang RF, Chen CZ, Tsai SH. Retinopathy, neuropathy and nephropathy in non-insulin-dependent diabetic patients. J Formos Med Assoc 1991. 90(10):936-940.
12. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001. 414(6865):813-820.
13. Wassef L, Langham RG, Kelly DJ. Vasoactive renal factors and the progression of diabetic nephropathy. Curr Pharm Des 2004. 10(27):3373-3384.
14. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011. 305(24):2532-2539.
15. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, Kasiske B, Kutner N, Liu J, St Peter W, et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis continuous support of epidemiologic studies in diabetes. Disclosures: The authors report no conflict of interests. 2012. 59(1 Suppl 1):A7.
16. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006. 69(11):2057-2063.
17. Barkoudah E, Skali H, Uno H, Solomon SD, Pfeffer MA. Mortality rates in trials of subjects with type 2 diabetes. J Am Heart Assoc 2012. 1(1):8-15.
18. Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin North Am 2006. 35(3):491-510.
19. Packard CJ, Saito Y. Non-HDL cholesterol as a measure of atherosclerotic risk. J Atheroscler Thromb 2004. 11(1):6-14.
20. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009. 5(3):150-159.
21. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004. 351(13):1296-1305.
22. Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of Vascular Disease in Diabetes. Diabetologia 2001. 44(Suppl 2):S54-S64.
23. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000. 106(4):453-458.
24. Avramoglu RK, Qiu W, Adeli K. Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation of hepatic and intestinal lipoprotein secretion. Front Biosci 2003. 8:464-476.
25. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009. 42(13-14):1331-1346.
26. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998. 21(1):69-75.
27. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003. 348(5):383-393.
28. Executive summary: Standards of medical care in diabetes 2012. Diabetes Care 2012. 35(Suppl 1):S4-S10.
29. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002. 106(25):3143-3421.
30. Howard BV, Robbins DC, Sievers ML, Lee ET, Rhoades D, Devereux RB, Cowan LD, Gray RS, Welty TK, Go OT, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler Thromb Vasc Biol 2000. 20(3):830-835.
31. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006. 29(6):1220-1226.
32. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008. 371(9607):117-125.
33. Tseng CH, Tseng CP, Chong CK, Cheng JC, Tai TY. Independent association between triglycerides and coronary artery disease in Taiwanese type 2 diabetic patients. Int J Cardiol 2006. 111(1):80-85.
34. Bos G, Dekker JM, Nijpels G, de Vegt F, Diamant M, Stehouwer CD, Bouter LM, Heine RJ. A combination of high concentrations of serum triglyceride and non-high-density-lipoprotein-cholesterol is a risk factor for cardiovascular disease in subjects with abnormal glucose metabolism-The Hoorn Study. Diabetologia 2003. 46(7):910-916.
35. Havel RJ. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol 2000. 11(6):615-620.
36. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004. 44(3):720-732.
37. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005. 366(9500):1849-1861.
38. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010. 362(17):1563-1574.
39. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011. 365(24):2255-2267.
40. Rosenson RS, AM Gotto Jr. When clinical trials fail to address treatment gaps: the failure of niacin-laropiprant to reduce cardiovascular events. Curr Atheroscler Rep 2013. 15(6):332.
41. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008. 359(21):2195-2207.
42. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010. 375(9716):735-742.
43. Wang KL, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 2012. 60(14):1231-1238.
44. Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, Kastelein JJ, Colhoun H, Barter P. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011. 57(14):1535-1545.
45. US Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol lowering statin drugs. www.fda.gov/Drugs/DrugSafety/ucm293101.htm.
46. Keane WF, Tomassini JE, Neff DR. Lipid abnormalities in patients with chronic kidney disease. Contrib Nephro 2011. 171:135-142.
47. Kimoto E, Shoji T, Emoto M, Miki T, Tabata T, Okuno Y, Ishimura E, Inaba M, Nishizawa Y. Effect of diabetes on uremic dyslipidemia. J Atheroscler Thromb 2002. 9(6):305-313.
48. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006. 290(2):F262-F272.
49. Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG. Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest 1996. 97(10):2167-2173.
50. Kim C, Vaziri ND. Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int 2005. 67(3):1028-1032.
51. Vaziri ND, Liang K. Down-regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int 1997. 51(3):913-919.
52. Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif 2011. 31(1-3):189-196.
53. Shoji T, Emoto M, Kawagishi T, Kimoto E, Yamada A, Tabata T, Ishimura E, Inaba M, Okuno Y, Nishizawa Y. Atherogenic lipoprotein changes in diabetic nephropathy. Atherosclerosis 2001. 156(2):425-433.
54. Yang X, So WY, Ma R, Ko G, Kong A, Lam C, Ho CS, Cockram C, Chow CC, Tong P, et al. Effects of albuminuria and renal dysfunction on development of dyslipidaemia in type 2 diabetes-the Hong Kong Diabetes Registry. Nephrol Dial Transplant 2008. 23(9):2834-2840.
55. Yamamoto T, So WY, Ma R, Ko G, Kong A, Lam C, Ho CS, Cockram C, Chow CC, Tong P, et al. Significant increase of apolipoprotein B48 levels by a standard test meal in type 2 diabetic patients with nephropathy. J Atheroscler Thromb 2008. 15(4):199-205.
56. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000. 58(1):293-301.
57. Shestakova MV, Koshel LV, Vagodin VA, Dedov II. Risk factors of diabetic nephropathy progression in patients with a long history of diabetic mellitus as shown by a retrospective analysis. Ter Arkh 2006. 78(5):60-64.
58. Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 2009. 24(4):1212-1219.
59. Shestakova MV, Chugunova LA, Shamkhalova M, Dirochka Iu A, Dedov II. Diabetic nephropathy: risk factors of rapid progression of renal failure. Ter Arkh 1999. 71(6):45-49.
60. Choi ME. Mechanism of transforming growth factor-beta1 signaling. Kidney Int Suppl 2000. 77: S53-S58.
61. Prakash J. Dyslipidemia in diabetic kidney disease. Clinical Queries Nephrology 2012. 1(2):115-118.
62. Wanner C, Greiber S, Kramer-Guth A, Heinloth A, Galle J. Lipids and progression of renal disease: role of modified low density lipoprotein and lipoprotein(a). Kidney Int Suppl 1997. 63:S102-106.
63. Rovin BH, Tan LC. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 1993. 43(1):218-225.
64. Lin J, Hu FB, Rimm EB, Rifai N, Curhan GC. The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. Kidney Int 2006. 69(2):336-342.
65. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998. 158(9):998-1004.
66. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997. 314(7083):783-788.
67. Cusick M, Chew EY, Hoogwerf B, Agron E, Wu L, Lindley A, Ferris FL 3rd. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26. Kidney Int 2004. 66(3):1173-1179.
68. Colhoun HM, Lee ET, Bennett PH, Lu M, Keen H, Wang SL, Stevens LK, Fuller JH. Risk factors for renal failure: the WHO Mulinational Study of Vascular Disease in Diabetes. Diabetologia 2001. 44(Suppl 2):S46-S53.
69. Kazumi T, Hozumi T, Ishida Y, Ikeda Y, Kishi K, Hayakawa M, Yoshino G. Increased urinary transferring excretion predicts microalbuminuria in patients with type 2 diabetes. Diabetes Care 1999. 22(7):1176-1180.
70. Tseng CH. Lipid abnormalities associated with urinary albumin excretion rate in Taiwanese type 2 diabetic patients. Kidney Int 2005. 67(4):1547-1553.
71. Pan J, Gao F, Bao Y, Zhang L, Tu Y, Jia W. Non-high-density lipoprotein cholesterol is associated more closely with albuminuria in Chinese type 2 diabetic patients with normal renal function, compared with traditional lipid parameters. J Clin Lipidol 2012. 6(4):382-387.
72. Tseng CH. Differential dyslipidemia associated with albuminuria in type 2 diabetic patients in Taiwan. Clin Biochem 2009. 42(10-11):1019-1024.
73. Bose S, Bomback AS, Mehta NN, Chen SC, Li S, Whaley-Connell A, Benjamin J, McCullough PA. Dysglycemia but not lipids is associated with abnormal urinary albumin excretion in diabetic kidney disease: a report from the Kidney Early Evaluation Program (KEEP). BMC Nephrol 2012. 13:104.
74. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl, 2005. 99:S87-S93.
75. Wei P, Grimm PR, Settles DC, Balwanz CR, Padanilam BJ, Sansom SC. Simvastatin reverses podocyte injury but not mesangial expansion in early stage type 2 diabetes mellitus. Ren Fail 2009. 31(6):503-513.
76. Zhu B, Shen H, Zhou J, Lin F, Hu Y. Effects of simvastatin on oxidative stress in streptozotocin-induced diabetic rats: a role for glomeruli protection. Nephron Exp Nephrol 2005. 101(1):e1-e8.
77. Lu L, Peng WH, Wang W, Wang LJ, Chen QJ, Shen WF. Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats. J Zhejiang Univ Sci B 2011. 12(8):652-659.
78. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001. 59(1):260-269.
79. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003. 361(9343):2005-2016.
80. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009. 54(5):810-819.
81. Luk AO, Yang X, Ma RC, Ng VW, Yu LW, Lau WW, Ozaki R, Chow FC, Kong AP, Tong PC, et al. Association of statin use and development of renal dysfunction in type 2 diabetes--the Hong Kong Diabetes Registry. Diabetes Res Clin Pract 2010. 88(3):227-233.
82. Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003. 19(7):615-617.
83. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005. 45(3):485-493.
84. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012. 60(5):850-886.
85. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005. 353(3):238-248.
86. Fellstrom BC, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009. 360(14):1395-1407.
87. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010. 160(5):785-794.
88. Holdaas H, Holme I, Schmieder RE, Jardine AG, Zannad F, Norby GE, Fellstrom BC. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol 2011. 22(7):1335-1341.
89. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011. 377(9784):2181-2192.
90. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007. 14(Suppl 2):S1-S113.
91. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010. 375(9731):2073-2081.
92. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005. 16(2):489-495.
93. Yokoyama H, Aoki T, Imahori M, Kuramitsu M. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity. Kidney Int 2004. 66(1):448-454.
94. Yu Y, Suo L, Yu H, Wang C, Tang H. Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria. Diabetes Res Clin Pract 2004. 65(2):95-104.
95. Wu T, McGrath KC, Death AK. Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers? Vasc Health Risk Manag 2005. 1(4):309-316.
96. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002. 51(4):1157-1165.
97. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989. 1(8636):461-463.
98. Bruno CM, Meli S, Marcinno M, Ierna D, Sciacca C, Neri S. Plasma endothelin-1 levels and albumin excretion rate in normotensive, microalbuminuric type 2 diabetic patients. J Biol Regul Homeost Agents 2002.16(2):114-117.
99. Hermans MM, Henry R, Dekker JM, Kooman JP, Kostense PJ, Nijpels G, Heine RJ, Stehouwer CD. Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study. J Am Soc Nephrol 2007. 18(6):1942-1952.
100. Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter LM. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction-the Hoorn Study. Kidney Int Suppl 2004. (92):S42-S44.
101. Hermans MM, Henry RM, Dekker JM, Nijpels G, Heine RJ, Stehouwer CD. Albuminuria, but not estimated glomerular filtration rate, is associated with maladaptive arterial remodeling: the Hoorn Study. J Hypertens 2008. 26(4):791-797.
102. Ko GT, So WY, Chan NN, Chan WB, Tong PC, Li J, Yeung V, Chow CC, Ozaki R, Ma RC, et al. Prediction of cardiovascular and total mortality in Chinese type 2 diabetic patients by the WHO definition for the metabolic syndrome. Diabetes Obes Metab 2006. 8(1):94-104.
103. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997. 157(13):1413-1418.
104. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001. 286(4):421-426.
105. Rein P, Vonbank A, Saely CH, Beer S, Jankovic V, Boehnel C, Breuss J, Risch L, Fraunberger P, Drexel H. Relation of albuminuria to angiographically determined coronary arterial narrowing in patients with and without type 2 diabetes mellitus and stable or suspected coronary artery disease. Am J Cardiol 2011. 107(8):1144-1148.
106. So WY, Kong AP, Ma RC, Ozaki R, Szeto CC, Chan NN, Ng V, Ho CS, Lam CW, Chow CC, et al. Glomerular filtration rate, cardiorenal end points, and allcause mortality in type 2 diabetic patients. Diabetes care 2006. 29(9):2046-2052.
107. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009. 20(8):1813-1821.
108. Tseng CH, Chong CK, Tseng CP, Tai TY. The association between urinary albumin excretion and anklebrachial index in elderly Taiwanese patients with type 2 diabetes mellitus. Age Ageing 2008. 37(1):77-82.
109. Tseng CH, Tseng CP, Tai TY, Chong CK. Effect of angiotensin blockade on the association between albuminuria and peripheral arterial disease in elderly Taiwanese patients with type 2 diabetes mellitus. Circ J 2005. 69(8):965-970.
110. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000. 355(9200):253-259.
111. Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 2002. 18(Suppl 3):S82-S85.
112. Shahinfar S, Dickson TZ, Ahmed T, Zhang Z, Ramjit D, Smith RD, Brenner BM. Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. Kidney Int Suppl 2002. 82:S64-S67.
113. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004. 110(8):921-927.
114. Ibsen H, Lindholm LH, Pedersen OL, Dahlof B, Kjeldsen S. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study. Ugeskr Laeger 2003. 165(5):459-462.
115. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002. 359(9311):1004-1010.
116. Holtkamp FA, de Zeeuw D, de Graeff PA, Laverman GD, Berl T, Remuzzi G, Packham D, Lewis JB, Parving HH, Lambers Heerspink HJ. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J 2011. 32(12):1493-1499.
117. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998. 352(9131):837-853.
118. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008. 359(15):1577-1589.
119. de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD, White NH, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 2011. 171(5):412-420.
120. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008. 358(24):2560-2572.
121. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008. 358(24):2545-2559.